We're excited to welcome Paulo Fontoura to our team! Paulo joins us as chief medical officer. He brings a wealth of experience and deep insight to help advance our mission of leveraging AI to transform drug discovery. We're thrilled he's on board for this journey. More info in today's announcement: https://bit.ly/3BxfbfO
Xaira Therapeutics
Biotechnology Research
Brisbane, CA 24,384 followers
an integrated biotechnology company driving advances in AI to transform how we treat disease.
About us
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
- Website
-
https://xaira.com/
External link for Xaira Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brisbane, CA
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Get directions
Brisbane, CA 94549, US
Employees at Xaira Therapeutics
Updates
-
When science meets AI, cool things happen … like earning a spot on Fortune’s 50 AI Innovators list! Thanks to John Kell for sitting down with our CEO, Marc Tessier-Lavigne, to learn more about how we're applying AI to drug discovery, production, and clinical trials. Marc says “We believe that AI will enable us to transform how we do all three steps and be much more successful.”
The Fortune 50 AI Innovators list is here.🎉 If you thought the pace of innovation or investor appetite for AI companies might cool off this year, you were in for a big surprise. Leading AI startups like OpenAI and Anthropic saw their valuations surge, while increasingly powerful large language models and new multi-modal capabilities such as voice pushed the envelope of the technology's mind-blowing potential ever further. That gave us a lot to work with as we surveyed the field for our second annual Fortune 50 AI Innovators list. As with the inaugural 2023 list, we cast a wide net, looking at companies of all sizes, from all over the world. In addition to OpenAI, the Big Tech companies on the list include Microsoft, chipmaker Nvidia, business software firm Salesforce, and Chinese e-commerce juggernaut Alibaba Group. Among the startups are voice cloning tech company ElevenLabs, French AI chatbot upstart Mistral AI, China-based AI company ModelBest, and biotechnology company Xaira Therapeutics—all of which are less than three years old. 🔗 See the full list: https://lnkd.in/gx-JDdHV
-
More Xair Bears! What a great Halloween at Xaira HQ. Oh hey Flavio Schwarz, Aisha Chow, Tina Thai, Marc Tessier-Lavigne, Thomas Bartholow, Norman Goodacre, Jared Mohr, Ankita W., James Maksymetz , Andy Deng, Hetu K, Danielle Brady, Jason Liang, Lauren Lau, Arvind Rajpal, Christine Beahn, and Debbie Law! Nice work.
-
-
Happy Halloween from our Xair Bears to yours! Hetu K, Debbie Law, Arvind Rajpal, Danielle Brady, Marc Tessier-Lavigne (we'll let you decide which one is Grumpy Bear)
-
-
Xaira in the Wild, Part 3 (and we do mean wild!), in which we highlight the employees who make us a #LinkedInTopStartup, as they do their thing outside of work. Join us for this magnificent view of our head of business operations, Pam Cheng, as she swims with a whale shark. Did you know that the whale shark is the largest living non-cetacean animal? And contrary to what its name implies, it is not a mammal but a fish. Here comes the part where we insert pithy little analogies (H/T Christopher Yohn, Ph.D.) about your career, and how you need to check out our open jobs so you can avoid swimming with sharks, and become a big fish in the AI drug discovery sea, etc. But we feel that cheapens the beauty of this video, so we'll stop here. Come swim with us: https://lnkd.in/gWRTQzED
-
Team Xaira in the Wild ... part 2 in a series. What makes Xaira a #LinkedInTopStartup? Our multi-faceted team of many talents, of course. Today we shine a spotlight on our scientist Elizabeth (Ryan) Rumsey, while she engages in her favorite after work activity: refurbishing furniture and re-imagining a brand new future for it. Does your career need a little refurbishing and restoring? Has the shine dulled? Are you drawn to our mission of reimagining the future of drug discovery through AI and sanding away all the rough edges? We'll stop with our weak analogies (or is it metaphors? We get those confused - pls advise us in the comments) and let you read our job description of the week. We're hiring for a head of computational biology and bioinformatics. Come bring your whole self to Xaira: https://lnkd.in/gtmjTZw4
-
Closing out a busy week with some news about our team! We're so excited to be working with Debbie Law and Julia Tran.
Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer
businesswire.com
-
Team Xaira in the wild! What makes Xaira a LinkedIn Top Startup? It's our people, of course. We hire people who are excited by and engaged in this crazy world around us. Today Sydney Gordon, a principal scientist in our drug development and discovery team, shows us what she gets up to when she's not getting her science on. What moves you? Check out our open roles here and bring your whole self to our team: https://lnkd.in/gWRTQzED
-
Congratulations from all of us at Xaira Therapeutics to our co-founder, David Baker, and to John Jumper and Demis Hassabis of Google DeepMind, for sharing this year’s Nobel Prize in Chemistry! Their stunning breakthroughs, using AI to enable prediction of protein structure and extending this to the design of novel proteins, have opened up the empirical world of drug discovery to the power of AI. Xaira was founded to leverage AI advances to transform how we discover and develop drugs and to generate novel therapies for poorly treated diseases. Congratulations to these three inspiring scientists for providing the foundation for our work!
BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 Nobel Prize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.” The Nobel Prize in Chemistry 2024 is about proteins, life’s ingenious chemical tools. David Baker has succeeded with the almost impossible feat of building entirely new kinds of proteins. Demis Hassabis and John Jumper have developed an AI model to solve a 50-year-old problem: predicting proteins’ complex structures. These discoveries hold enormous potential. The diversity of life testifies to proteins’ amazing capacity as chemical tools. They control and drive all the chemical reactions that together are the basis of life. Proteins also function as hormones, signal substances, antibodies and the building blocks of different tissues. Proteins generally consist of 20 different amino acids, which can be described as life’s building blocks. In 2003, David Baker succeeded in using these blocks to design a new protein that was unlike any other protein. Since then, his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors. The second discovery concerns the prediction of protein structures. In proteins, amino acids are linked together in long strings that fold up to make a three-dimensional structure, which is decisive for the protein’s function. Since the 1970s, researchers had tried to predict protein structures from amino acid sequences, but this was notoriously difficult. However, four years ago, there was a stunning breakthrough. In 2020, Demis Hassabis and John Jumper presented an AI model called AlphaFold2. With its help, they have been able to predict the structure of virtually all the 200 million proteins that researchers have identified. Since their breakthrough, AlphaFold2 has been used by more than two million people from 190 countries. Among a myriad of scientific applications, researchers can now better understand antibiotic resistance and create images of enzymes that can decompose plastic. Life could not exist without proteins. That we can now predict protein structures and design our own proteins confers the greatest benefit to humankind. Learn more Press release: https://bit.ly/3TM8oVs Popular information: https://bit.ly/3XYHZGp Advanced information: https://bit.ly/4ewMBta
-
-
Still having a warm glow from last week's Endpoints 11 awards ceremony in Boston! Here is Xaira Therapeutics CEO Marc Tessier-Lavigne with Vik Bajaj, CEO of Foresite Labs, at the gala dinner. Xaira is a joint incubation of ARCH Venture Partners and Foresite Labs. A lot of people have been hard at work building our foundation - shout out to our employees 🚀 for helping us get this recognition! Have a safe and happy weekend from Xaira HQ.
-